Obesity related adipokines and colorectal cancer: A review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 1, 2014, Pages 397-405

  Joshi, Rakhi Kumari ^a   Lee, Sang Ah ^a  

^a Kangwon National University College of Medicine   (South Korea)

Author keywords

Adipokines; Colorectal cancer; Obese related adipokines; Obesity; Risk factors

Indexed keywords

ADIPONECTIN; INTERLEUKIN 6; LEPTIN; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; BODY MASS; COLORECTAL TUMOR; HUMAN; INFLAMMATION; META ANALYSIS; OBESITY; REVIEW; RISK FACTOR; WAIST CIRCUMFERENCE;

ADIPONECTIN; BODY MASS INDEX; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEPTIN; OBESITY; RESISTIN; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; WAIST CIRCUMFERENCE;

EID: 84894047236     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.1.397     Document Type: Review

References (67)

1. Aleksandrova K, Boeing H, Jenab M, et al (2012). Leptin and soluble leptin receptor in risk of colorectal cancer in the European prospective investigation into cancer and nutrition cohort. Cancer Res, 72, 5328-37.
2. Aleksandrova K, Boeing H, Jenab M, et al (2012). Total and high-molecular weight adiponectin and risk of colorectal cancer: the European prospective investigation into cancer and nutrition study. Carcinogenesis, 33, 1211-8.
3. Aleksandrova K, Nimptsch K, Pischon T (2013). Influence of obesity and related metabolic alterations on colorectal cancer risk. Current nutrition reports, 2, 1-9.
4. An W, Bai Y, Deng SX, et al (2012). Adiponectin levels in patients with colorectal cancer and adenoma: a meta-analysis. Eur J Cancer Prev, 21, 126-33.
5. Arpaci F, Yilmaz MI, Ozet A, et al (2002). Low serum leptin level in colon cancer patients without significant weight loss. Tumori, 88, 147-9.
6. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS (2007). Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr, 86, 858-66.
7. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
8. Bokarewa M, Nagaev I, Dahlberg L, et al (2005). Resistin, an adipokine with potent proinflammatory properties. J Immunol, 174, 5789-95.
9. Chan AT, Ogino S, Giovannucci EL, Fuchs CS (2011). Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterol, 140, 799-808.
10. Chen MW, Ye S, Zhao LL, et al (2012). Association of plasma total and high-molecular-weight adiponectin with risk of colorectal cancer: an observational study in Chinese male. Med Oncol, 29, 3129-35.
11. Cochran W (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
12. Considine RV, Sinha MK, Heiman ML, et al (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med, 334, 292-5.
13. Cottam DR, Mattar SG, Barinas-Mitchell E, et al (2004). The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg, 14, 589-600.
14. Dai Z, Xu YC, Niu L (2007). Obesity and colorectal cancer risk: a meta-analysis of cohort studies. World J Gastroenterol, 13, 4199-206.
15. Danese E, Montagnana M, Minicozzi AM, et al (2012). The role of resistin in colorectal cancer. Clin Chim Acta, 413, 760-4.
16. Dersimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
17. Eder K, Baffy N, Falus A, Fulop AK (2009). The major inflammatory mediator interleukin-6 and obesity. Inflamm Res, 58, 727-36.
18. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
19. Erarslan E, Turkay C, Koktener A, et al (2009). Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci, 54, 862-8.
20. Fantuzzi G (2005). Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol Pract, 115, 911-9.
21. Fernandez-Real JM, Ricart W (2003). Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev, 24, 278-301.
22. Friedman JM, Halaas JL (1998). Leptin and the regulation of body weight in mammals. Nature, 395, 763-70.
23. Fruhbeck G (2006). Intracellular signalling pathways activated by leptin. Biochem J, 393, 7-20.
24. Gialamas SP, Petridou ET, Tseleni-Balafouta S, et al (2011). Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism, 60, 1530-8.
25. Gialamas SP, Sergentanis TN, Antonopoulos CN, et al (2013). Circulating leptin levels and risk of colorectal cancer and adenoma: a case-control study and meta-analysis. Cancer Causes Control, 24, 2129-41.
26. Gonullu G, Kahraman H, Bedir A, et al (2010). Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Colorectal Dis, 25, 205-12.
27. Gs HJ (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [update March 2011]. The Cochrane Collabration 2011.
28. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8.
29. Gunter MJ, Hoover DR, Yu H, et al (2008). Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res, 68, 329-37.
30. Heikkila K, Harris R, Lowe G, et al (2009). Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control, 20, 15-26.
31. Ho GY, Wang T, Gunter MJ, et al (2012). Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res, 72, 3029-37.
32. Il'yasova D, Colbert LH, Harris TB, et al (2005). Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev, 14, 2413-8.
33. Kawanami D, Maemura K, Takeda N, et al (2004). Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun, 314, 415-9.
34. Kemik O, Sumer A, Kemik AS, et al (2010). The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer. World J Surg Oncol, 8, 85.
35. Kern PA, Ranganathan S, Li C, et al (2001). Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab, 280, 745-51.
36. Knupfer H, Preiss R (2010). Serum interleukin-6 levels in colorectal cancer patients a summary of published results. Int J Colorectal Dis, 25, 135-40.
37. Kubota N, Terauchi Y, Yamauchi T, et al (2002). Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem, 277, 25863-6.
38. Kumada M, Kihara S, Ouchi N, et al (2004). Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages. Circulation, 109, 2046-9.
39. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009). Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis, 24, 275-81.
40. Larsson SC, Wolk A (2007). Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr, 86, 556-65.
41. Lee S, Choe JW, Kim HK, Sung J (2011). High-sensitivity C-reactive protein and cancer. J Epidemiol, 21, 161-8.
42. Lotem J, Sachs L (1998). Different mechanisms for suppression of apoptosis by cytokines and calcium mobilizing compounds. Proc Natl Acad Sci U S A, 95, 4601-6.
43. Lukanova A, Söderberg S, Kaaks R, Jellum E, Stattin P (2006). Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev, 15, 401-2.
44. Mantel N & Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
45. Moghaddam AA, Woodward M and Huxley R (2007). Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev, 16, 2533-47.
46. Nagaev I & Smith U (2001). Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun, 285, 561-4.
47. Nakajima TE, Yamada Y, Hamano T, et al (2010). Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci, 101, 1286-91.
48. Ning Y, Wang L, Giovannucci EL (2010). A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev, 11, 19-30.
49. Otake S, Takeda H, Fujishima S, et al (2010). Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol, 16, 1252-7.
50. Pais R, Silaghi H, Silaghi AC, et al (2009). Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol, 15, 5141-8.
51. Paz-Filho G, Lim EL, Wong ML, Licinio J (2011). Associations between adipokines and obesity-related cancer. Front Biosci (Landmark Ed), 16, 1634-50.
52. Reilly MP, Lehrke M, Wolfe ML, et al (2005). Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 111, 932-9.
53. Roberts DL, Dive C, Renehan AG (2010). Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med, 61, 301-16.
54. Salageanu A, Tucureanu C, Lerescu L, et al (2010). Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life, 3, 416-20.
55. Sierra-Honigmann MR, Nath AK, Murakami C, et al (1998). Biological action of leptin as an angiogenic factor. Science, 281, 1683-6.
56. Simons PJ, van den Pangaart PS, van Roomen CP, Aerts JM, Boon L (2005). Cytokine-mediated modulation of leptin and adiponectin secretion during in vitro adipogenesis: evidence that tumor necrosis factor-alpha-and interleukin-1beta-treated human preadipocytes are potent leptin producers. Cytokine, 32, 94-103.
57. Stattin P, Lukanova A, Biessy C, et al (2004). Obesity and colon cancer: does leptin provide a link? Int J Cancer, 109, 149-52.
58. Stattin P, Palmqvist R, Soderberg S, et al (2003). Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep, 10, 2015-21.
59. Stocks T, Lukanova A, Johansson M, et al (2008). Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond), 32, 304-14.
60. Tamakoshi K, Toyoshima H, Wakai K, et al (2005). Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncol, 68, 454-61.
61. Tilg H, Moschen AR (2006). Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nature reviews Immunol, 6, 772-83.
62. Touvier M, Fezeu L, Ahluwalia N, et al (2012). Pre-diagnostic levels of adiponectin and soluble vascular cell adhesion molecule-1 are associated with colorectal cancer risk. World J Gastroenterol, 18, 2805-12.
63. Wei EK, Giovannucci E, Fuchs CS, et al (2005). Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst, 97, 1688-94.
64. Wolf AM, Wolf D, Rumpold H, et al (2004). Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun, 323, 630-5.
65. Xu XT, Xu Q, Tong JL, et al (2011). Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis, 12, 234-44.
66. Yamauchi T, Kamon J, Minokoshi Y, et al (2002). Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 8, 1288-95.
67. Yokota T, Oritani K, Takahashi I, et al (2000). Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood, 96, 1723-32.